Diapositive 1 - Groupe Francophone thrombose et cancer

I. ELALAMY
Service'd’Hématologie'Biologique
HOPITAL TENON –ER2 UPMC PARIS
GFTC
CANCER DU SEIN :
HORMONOTHERAPIE ET
RISQUE THROMBOTIQUE

Silver In: The Hematologist - modified from Blom et. al. JAMA 2005;293:715
•Population-based MEGA study
•N=3220 consecutive patients with 1st VTE
vs. n=2131 control subjects
•CA patients = OR 7x VTE risk vs. non-CA
patients
Cancer et Risque Thromboembolique Veineux
0
10
20
30
40
50
Hematological
Lung
Gastrointestinal
Breast
Distant
metastases
0 to 3 months
3 to 12 months
1 to 3 years
5 to 10 years
> 15 years
Adjusted odds ratio
Type of cancer Time since cancer diagnosis
28
22.2 20.3
4.9
19.8
53.5
14.3
2.6 1.1
3.6

Paneesha et al,
Thromb Haemost 2010
Site du Cancer
et risque MTEV

Cancer et MTEV chez patients non hospitalisés
Age de survenue
Paneesha et al, Thromb Haemost 2010

Cancer et MTEV chez patients non hospitalisés
Sexe
Paneesha et al, Thromb Haemost 2010